Astrana Health’s stock plummeted 16.7% after reporting Q3 earnings that missed profit expectations and lowering its full-year financial outlook. Revenue grew 99.7% to $956 million, beating estimates, but earnings per share were only $0.01, far below the forecast of $0.43. The company reduced its full-year revenue guidance to $3.14 billion and adjusted EBITDA to $205 million, both below analyst expectations. The stock has been volatile, with 23 moves greater than 5% in the past year. Investors are wondering if now is the time to buy Astrana Health.

In contrast, Astrana Health’s stock rose 34.2% three months ago when it reported better-than-expected Q2 sales and raised its full-year revenue forecast. Second-quarter revenue was $654.8 million, up 34.7% year-over-year, but GAAP profit was below estimates. The company raised its full-year revenue guidance to $3.2 billion and projected third-quarter revenue to be $945 million, 17.2% higher than analysts’ expectations. The stock is down 13.9% since the beginning of the year and trading 53.1% below its 52-week high.

The market may be overreacting to Astrana Health’s recent news, as big price drops can present buying opportunities. The company has shown strong sales growth but faces challenges with earnings and guidance. The stock has been highly volatile, with significant moves impacting investor perception. Investors should carefully consider the company’s financial outlook before making any decisions.

Read more at Yahoo Finance: Why Astrana Health (ASTH) Shares Are Plunging Today